TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BDGKMY29
Issuer Name
BIOPHARMA CREDIT PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An event changing the breakdown of voting rights
3. Details of person subject to the notification obligation
Name
Adage Capital Management L.P.
City of registered office (if applicable)
Country of registered office (if applicable)
US
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Adage Capital Partners, L.P. |
|
|
5. Date on which the threshold was crossed or reached
09-Feb-2024
6. Date on which Issuer notified
19-Nov-2024
7. Total positions of person(s) subject to the notification obligation
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
|
Resulting situation on the date on which threshold was crossed or reached |
13.010000 |
0.000000 |
13.010000 |
164014169 |
|
Position of previous notification (if applicable) |
12.000000 |
0.000000 |
12.000000 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB00BDGKMY29 |
0 |
164014169 |
0.000000 |
13.010000 |
|
Sub Total 8.A |
164014169 |
13.010000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
Adage Capital Management, LP |
Adage Capital Partners GP, L.L.C. (as general partner of Adage Capital Partners, L.P.) |
13.010000 |
|
13.010000% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Our filing is late because we misunderstood how the incremental reporting thresholds apply to Biopharma Credit PLC under DTR 5. We have now taken legal advice and implemented procedures to monitor and report our positions in accordance with our obligations under DTR 5.
12. Date of Completion
19-Nov-2024
13. Place Of Completion
London, England
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
